Lansoprazole vs Pantoprazole
Overview
Lansoprazole and pantoprazole are both effective PPIs, but pantoprazole's minimal CYP2C19 inhibitory activity gives it a clear advantage in patients on antiplatelet or other CYP2C19-sensitive drugs.
Mechanism of Action
Both irreversibly inhibit H+/K+-ATPase. Both require enteric coating or delayed-release formulation to reach the duodenum intact.
Pharmacokinetics
Lansoprazole: CYP2C19 + CYP3A4 metabolism. Pantoprazole: CYP2C19 + CYP3A4, but pantoprazole inhibits CYP2C19 much less potently than lansoprazole. Both have ~1–1.5 h half-lives with IV formulations available.
Clinical Evidence
Equivalent efficacy for GERD, peptic ulcer, and H. pylori eradication. Pantoprazole's IV formulation is extensively used in hospital settings. Lansoprazole's SoluTab (ODT) is useful for nasogastric tube administration.
Key Takeaways
- Pantoprazole: fewer drug interactions, preferred with clopidogrel
- Lansoprazole: SoluTab ODT formulation unique advantage
- Both available as IV; equivalent for standard indications
Fazit
Pantoprazole is preferred with clopidogrel or other CYP2C19-sensitive drugs. Lansoprazole SoluTab is preferred for patients with swallowing difficulties or nasogastric tube administration. For standard outpatient GERD, both are equivalent.